Published in

Oxford University Press, Stem Cells Translational Medicine, 11(6), p. 2044-2052, 2017

DOI: 10.1002/sctm.17-0081

Links

Tools

Export citation

Search in Google Scholar

Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke: EVs and Stroke Therapy

Journal article published in 2017 by Thorsten R. Doeppner ORCID, Mathias Bähr, Dirk M. Hermann, Bernd Giebel
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Abstract Despite recent advances in stroke therapy, current therapeutic concepts are still limited. Thus, additional therapeutic strategies are in order. In this sense, the transplantation of stem cells has appeared to be an attractive adjuvant tool to help boost the endogenous regenerative capacities of the brain. Although transplantation of stem cells is known to induce beneficial outcome in (preclinical) stroke research, grafted cells do not replace lost tissue directly. Rather, these transplanted cells like neural progenitor cells or mesenchymal stem cells act in an indirect manner, among which the secretion of extracellular vesicles (EVs) appears to be one key factor. Indeed, the application of EVs in preclinical stroke studies suggests a therapeutic role, which appears to be noninferior in comparison to the transplantation of stem cells themselves. In this short review, we highlight some of the recent advances in the field of EVs as a therapeutic means to counter stroke.